Skip to main content
. 2020 Feb 11;21(3):316–324. doi: 10.3348/kjr.2019.0647

Fig. 3. Survival rates between RFA group and chemotherapy group.

Fig. 3

Overall survival from date of diagnosis of hepatic metastases (A) and from date of initial RFA (B) in 60 patients. C. Median overall survival from initial treatment was higher in RFA group (12 months) than in chemotherapy group (9.1 months), but difference was not statistically significant (p = 0.094). D. Median progression-free survival from initial treatment was higher in RFA group (5 months) than in chemotherapy group (3.3 months), but difference was marginally significant (p = 0.068).